PNU-177864

PNU-177864 is a potent, selective, orally active dopamine D3 receptor antagonist. PNU-177864 induces phospholipid metabolism in vivo and has anti-schizophrenia activity[1][2][3].

Product Specifications

CAS Number

[250266-51-4]

UNSPSC

12352005

Target

CCR; Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pnu-177864.html

Purity

99.49

Solubility

DMSO : 57.14 mg/mL (adjust pH to 5 with HCl)

Smiles

O=S(C1=CC=C(OC(F)(F)F)C=C1)(NC2=CC=C(CCNCCC)C=C2)=O

Molecular Formula

C18H21F3N2O3S

Molecular Weight

402.43

References & Citations

[1]Rudmann DG, et al. Epididymal and systemic phospholipidosis in rats and dogs treated with the dopamine D3 selective antagonist PNU-177864. Toxicol Pathol. 2004 May-Jun;32 (3) :326-32.|[2]Vonderfecht SL, et al. Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence. Toxicol Pathol. 2004 May-Jun;32 (3) :318-25.|[3]Liana Basova , et al. Dopamine and its receptors play a role in the modulation of CCR5 expression in innate immune cells following exposure to Methamphetamine: Implications to HIV infection. PLoS One.2018 Jun 26;13 (6) :e0199861.